Introduction {#sec1-1}
============

Adoptive cell transfer (ACT) represents an important advance in cancer immunotherapy. The success of ACT depends on the functional quality of cells transferred \[**[@R1]**\]. Upon antigen (Ag) recognition, early effector CD8+ T cells are characterized by the expression of high levels of the lymphoid homing molecule CD62L or L--selectin. The expression of CD62L decreases together with the activation progresses, with a re--expression almost restricted to central memory cells \[**[@R2]--[@R3]**\]. It is believed that the enhanced anti--Ag activity associated with T cells expressing high levels of CD62L, related to their ability to home the secondary lymph nodes, where effective stimulation can take place \[**[@R4]**\]. Thus, approaches aimed at the generation and maintenance of early effector populations could be valuable in the development of effective ACT--based immunotherapies for cancer. Because cytokines are known to play fundamental roles in the differentiation and maturation of Ag reactive T cells, cytokine conditioning prior to cell transfer has been considered as a means of increasing the proliferation and function of these cells \[**[@R5]**\]. Interleukin--2 and interleukin--15 (IL--2, IL--15) are key participants in T and NK cell activation and function \[**[@R6]**\]. Sharing the beta and gamma--receptor subunits, such as the promotion of T cell proliferation, results in several common functions. On the other hand, due to their distinct alpha--receptor subunits, they also play opposing roles in immune processes such as activation--inducing cell death \[**[@R6]**\].

However, IL--2 and IL--15 could both induce apoptosis and survival; the outcome depends on the cytokine concentration \[**[@R7]**\]. Of significant interest is the role of IL--12. In addition to its role in polarizing Th1 responses and in the maturation of cytotoxic function of NK cells \[**[@R8]**\], IL--12 acts as a third signal along with Ag and IL--2 on naïve CD8+ T cells, increasing the pool of effector and memory cells, two crucial components of a successful ACT approach \[**[@R9]--[@R10]**\]. Evidence for this has been provided in recent reports demonstrating increased anti--tumor capabilities of CD8+ T cells after *ex vivo* and *in vitro* culture in the presence of IL--12 \[**[@R11]--[@R12]**\].

Increasing evidence indicated that insulin--like growth factor--1 (IGF--1) is involved in the function and development of the immune system. IGF--1 may alter homeostasis in the immune system by modulating lymphocyte generation and survival \[**[@R13]**\].

*In vivo* treatment with IGF--1 enhanced thymic reconstitution in steroid--treated \[**[@R14]**\], aged \[**[@R15]**\], and diabetic \[**[@R16]**\] animals. Hettmer *et al.* \[**[@R17]**\] suggested a role for IGF binding protein as a local growth factor contributing to the proliferation and activation of mononuclear cells. The role of IGF--1 in the regulation of apoptosis has also been suggested both *in vivo* and *in vitro* \[**[@R18]**\]. The production of IGF--1 by thymic epithelial cells \[**[@R19]**\] and the increased IGF--1 receptor expression on T cells after *in vitro* activation with anti--CD3 antibody \[**[@R20]**\] suggested that IGF--1 may play a role in the T cell selection process.

Thymosin--α1 (T--α1), initially isolated from thymus, is now proved to be effective in inhibiting tumoral growth and in controlling infective diseases. Different studies evaluated its immunomodulating effects and showed that T-- α1 increased major histocompatibility complex (MHC) class--1, antagonized dexamethasone--induced apoptosis of CD4+CD8+ thymocytes \[**[@R21]**\], primed dendritic cells for antifungal T--helper type 1 resistance through Toll--like receptor signaling \[**[@R22]**\], reduced pancreatic inflammation by regulating differentiation of CD3/CD4+ T cells \[**[@R23]**\] and increased cytokine production. Vitamin A and its metabolite all transretinoic acid (ATRA) have attracted considerable attention as compounds that have a broad range of immune modulating effects on both humoral and cellular immune responses. It was demonstrated that the topical retinoids have significant anti--inflammatory effects in experimental trials \[**[@R24]**\]. While ATRA downregulated the proinflammatory cytokines, the production of immune modulating cytokines was enhanced by ATRA \[**[@R25]**\]. ATRA induced a \"priming\" of the immune system by increasing the number of T lymphocytes and LPS binding protein expression \[**[@R26]**\], and stimulated T cell proliferation by modulating IL--2--mediated signaling \[**[@R27]**\]. ATRA has been used as monotherapy for treatment of cutaneous T--cell lymphomas for years \[**[@R28]**\]. The combination of ATRA and IFN--gamma could become an efficacious chemoimmunotherapy for the treatment of human glioblastoma \[**[@R29]**\]. ATRA also showed potent effects on hemopoietic stem cell integrity, inhibiting the expansion of human progenitor cells and accelerating their differentiation to B lineage cells \[**[@R30]**\].

The aim of the present study was to define the immunomodulatory factors that can increase survival and sustain CD62L expression in antigen--specific T cells. To this end, the effects of IL--2, IL--12, IL--15, IGF--1, T-- α1 as well as ATRA alone or in combination were tested *in vitro* utilizing OT1 transgenic T cells as a model.

Materials and methods {#sec1-2}
=====================

**Mice:** OT--1 T cell receptor (TCR) transgenic mice on C57Bl/6 (B6) background were purchased from Jackson Laboratory (Bar Harbor, ME). OT--1 mice were bred with B6.SJL mice to generate Ly5.1+/Ly5.1+ mice heterozygous for the OT--1 TCR (Vα2/Vα5) transgene confirmed by flow cytometry with monoclonal antibody (mAb) specific for Vα2. All animals were housed under specific pathogen--free conditions in accordance with institutional and federal guidelines at the Medical University of South Carolina, USA.

**Antibodies and reagents:** Anti--CD16/CD32, and FITC--, PE--, APC--, and cychrome--conjugated monoclonal antibodies (mAbs) were purchased from Pharmingen, San Diego, CA. The major histocompatability (MHC) class--I SIINFEKL OVA peptide (OVAp) (American Peptide Company, Inc., Sunnyvale, CA) was dissolved in 10% DMSO (Sigma, St. Louis, MO) and diluted in phosphate buffered solution (PBS). Cytokines IL--2, IL--12, and IL--15 (Systems, Minneopolis, MN) were stored as a lyophilized powder at --20°C, and reconstituted immediately prior to use in 0.1% bovine serum albumin (BSA) in PBS. IGF--1, T--α1, and ATRA were purchased from Sigma, San Diego, CA.

A**ntigen--induced T cell activation:** OT--1 cells were prepared and cultured as previously described by Salem et al. \[**[@R31]**\]. In brief, one or 2 OT--1 mice were sacrificed and spleens and peripheral (cervical, auxiliary, brachial, and inguinal) and mesenteric lymph nodes were harvested and pooled. Single cell suspension was prepared in PBS by grinding these tissues between the 2 rough ends of microscopic slides. Cells were washed twice and re--suspended in RPMI medium. Unfractionated OT--1 cells (1 × 105) were cultured in triplicate in 6--well plate for 3 days in RPMI medium containing 1 μg/ml OVAp and the tested growth factors at the dose indicated in each experiment. Cells were harvested and washed twice and were freshly processed for the activation phenotype and apoptosis measured by flow cytometry.

**Measuring T cell activation by flow cytometry:** Staining for flow cytometry was performed as previously described by Salem et al. \[**[@R31]**\]. Fresh cells (0.5--1 × 106) were treated with anti--CD16/CD32 for 5 minutes on ice and then stained with the indicated conjugated mAbs, and incubated for 30 min on ice. The cells were washed twice and resuspended in 0.3 ml of 0.5% BSA, 0.02% sodium azide solution. Cells were washed, and analyzed by flow cytometry using the Cell Quest software package (Becton Dickinson, San Jose, CA).

**Measuring apoptosis by flow cytometry:** To measure apoptosis, cells were stained for the surface markers as described above and cells were then washed twice with FCAS buffer and twice with Annexin--V binding buffer (Pharmingen). Cells were incubated at room temperature for 15 minutes and then washed and analyzed immediately by flow cytometry.

Results {#sec1-3}
=======

CD8+ T cells stimulated with Ag showed higher levels of CD69 and lower levels of CD62L expression, compared to the CD69 and CD62L expression on unstimulated CD8+ T cells, on day 3 indicating their simulation. Of Note, the decrease in CD62L expression after Ag stimulation was further augmented on day 5 post--stimulation. Addition of IL--2, IL--12 or IL-- 15 to CD8+ T cells culture during Ag stimulation did not alter the phenotypic activation of CD8+ T cells when cells were harvested on day 3. The expression of CD62L assessed on CD8+ T cells on day 5 was much lower than on day 3. However, only CD8+ T cells that had conditioned with IL--12 showed higher levels of CD62L (**[Fig. 1](#F1){ref-type="fig"}**).

![Impacts of cytokines on the antigen-specific activation of CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide (SIINFEKL) from OVA albumin in the presence or absence of 10 ng/ml of interleukin (IL)--2, IL--12, or IL--15 cytokines. Cells were harvested on day 3 to assay expression of the early activation receptors CD69 and CD62L (A) and on day 5 to analyze the expression of only CD62L (B).](JMedLife-04-399-g001){#F1}

Addition of IGF--1 alone or in combination with IL--2, IL--12 or IL--15 to CD8+ T cells culture during Ag stimulation did not significantly alter the expression of either CD69 or CD62L on CD8+ T cells on day 3. The expression of CD62L assessed on CD8+ T cells on day 5 was much lower than on day 3. However, only CD8+ T cells that had been conditioned with combined IGF--1 and IL--12 showed higher levels of CD62L expression. The magnitude of this increase reached about 6--folds of the corresponding values of Ag stimulated CD8+ T cells (**[Fig. 2](#F2){ref-type="fig"}**).

![Impacts of cytokines on the activation induced cell death of antigen--stimulated CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of 10 ng/ml of IL--2, IL--12, or IL--15 cytokines. Cells were harvested on days 3 and 5 and their early apoptosis was analyzed by annexin--v assay.](JMedLife-04-399-g002){#F2}

Addition of T--α1 alone or in combination with IL--2, IL--12 or IL--15 to CD8+ T cells culture during Ag stimulation did not alter the expression of either CD69 or CD62L on CD8+ T cells on day 3. The expression of CD62L assessed on CD8+ T cells on day 5 was much lower than on day 3. However, only CD8+ T cells that had been conditioned with T--α1 and IL--12 in combination showed higher levels of CD62L expression. The magnitude of this increase reached about 3--folds of the corresponding values of Ag--stimulated CD8+ T cells (**[Fig. 3](#F3){ref-type="fig"}**).

![Impacts of a combinatorial treatment with IGF and cytokines on the antigen--specific activation of CD8+ T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of 10ng/ml insulin growth factor (IGF). Then, cells stimulated with IGF were further conditioned with either 10ng/ml IL--2, IL--12, or IL--15 cytokines. Cells were harvested on day 3 to assay expression of the early activation receptors CD62L and CD69 (A) and on day 5 to analyze the expression of only CD62L (B).](JMedLife-04-399-g003){#F3}

Addition of ATRA with doses 1, 5, 10 or 15 μM to CD8+ T cells culture during Ag stimulation did not alter the expression of CD62L on CD8+ T cells on day 3. The expression of CD62L assessed on CD8+ T cells on day 5 was much lower than on day 3. However, only CD8+ T cells that had been conditioned with ATRA with doses 10 and 15 μM showed higher levels of CD62L expression. The magnitude of this increase reached about 2.8-- and 3--folds of the corresponding values of Ag--stimulated CD8+ T cells, respectively (**[Fig. 4](#F4){ref-type="fig"}**).

![Impacts of a combinational treatment with IGF and cytokines on the antigen-specific activation of CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 x 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of 10ng/ml insulin growth factor (IGF). Cells stimulated with IGF were also conditioned with either 10 ng/ml IL--2, IL--12, or IL--15 cytokines. Cells were harvested on days 3 and 5 and their early apoptosis was analyzed by annexin--v assay.](JMedLife-04-399-g004){#F4}

Addition of ATRA with doses 1, 5, 10 or 15 μM in combination with IL--12 to CD8+ T cells culture during Ag stimulation did not alter the expression of CD62L on CD8+ T cells on day 3. The expression of CD62L assessed on CD8+ T cells on day 5 was much lower than on day 3. However, only CD8+ T cells that had been conditioned with ATRA with doses 5, 10 and 15 μM showed higher levels of CD62L expression. The magnitude of this increase reached about 2.7--, 3-- and 3.7--folds of the corresponding values of Ag--stimulated CD8+ T cells, respectively (**[Fig. 5](#F5){ref-type="fig"}**).

![Impacts of a combinatorial treatment with thymosin and cytokines on the antigen--specific activation of CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of 10 ng/ml thymosin (Thym). Cells stimulated with Thym were also conditioned with either 10 ng/ml IL--2, IL--12, or IL--15 cytokines. Cells were harvested on day 3 to assay expression of the early activation receptors CD62L and CD69 (A) and on day 5 to analyze the expression of only CD62L (B).](JMedLife-04-399-g005){#F5}

To test whether conditioning CD8+ T cells with IL--2, IL--12 or IL--15 impacts on Ag--induced T cells apoptosis, expression of Annexin V, as a marker of apoptosis, was measured by flow cytometry. It was found that stimulation of cells with Ag alone induced about 40% of the cultured cells to undergo apoptosis on day 3, which further augmented on day 5. Treatment of CD8+ T cells with only IL--12, but not IL--2 or IL--15 decreased the apoptosis level of CD8+ T cells by about 41% of the corresponding value of Ag--stimulated CD8+ T cells when measured on day 3. This anti--apoptotic effect of IL--12, however, was lost by day 5 (**[Fig. 6](#F6){ref-type="fig"}**).

![Impacts of a combinational treatment with Thym and cytokines on the antigen--specific activation of CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of 10 ng/ml thymosin (Thym). Cells stimulated with Thym were also conditioned with either 10 ng/ml, IL--2, IL--12, or IL--15 cytokines. Cells were harvested on days 3 and 5 and their early apoptosis was analyzed by annexin--v assay.](JMedLife-04-399-g006){#F6}

Treatment of CD8+ T cells with IGF--1 alone or in combination with IL--12 or IL--15, but not IL--2, decreased the percentage of apoptosis of these cells by about 51.1 and 62.9% of the corresponding value of Ag--stimulated CD8+ T cells, respectively, when measured on day 3. However, the anti--apoptotic effect of IGF--1 alone or in combination with IL--12 or IL--15 was less pronounced on day 5 (**[Fig. 7](#F7){ref-type="fig"}**).

![Impacts of treatment with different concentration of ATRA on the antigen-specific activation of CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of the indicated concentrations of ATRA. Cells were harvested on day 3 to assay expression of the early activation receptors CD62L and CD69 (A) and on day 5 to analyze the expression of only CD62L (B).](JMedLife-04-399-g007){#F7}

Combined treatment of CD8+ T cells with only T--α1 and IL--12, but not T--α1 alone or in combination with IL--2 or IL--15, decreased the percentage of apoptosis of these cells by about 47.5% of the corresponding value of Agstimulated CD8+ T cells when measured on day 3. However, the anti--apoptotic effect of a combined treatment with T--α1 and IL--12 was less pronounced by day 5 (**[Fig. 8](#F8){ref-type="fig"}**).

![Impacts of a combinatorial treatment with ATRA and IL--12 on the antigen--specific activation of CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of different concentration of ATRA. Cells stimulated with ATRA were concomitantly treated with 10 ng/ml IL--12. Cells were harvested on day 3 to assay expression of the early activation receptors CD62L and CD69 (A) and on day 5 to analyze the expression of only CD62L (B).](JMedLife-04-399-g008){#F8}

Treatment of CD8+ T cells with ATRA (1 and 10 μM), but not 5 or 15 μg, decreased the percentage of apoptosis of these cells by about 49.2 and 44.7% of the corresponding value of Ag\#x2013;stimulated CD8+ T cells, respectively when measured on day 3. However, the anti--apoptotic effect of ATRA treatment with doses 1 and 10 μg was abrogated by day 5 (**[Fig. 9a](#F9){ref-type="fig"}**). Combined treatment of CD8+ T cells with ATRA (1, 5, 10 and 15 μM) and IL--12 decreased the percentage of apoptosis of these cells by about 67.0, 70.1, 66.5 and 65.8% of the corresponding value of Ag--stimulated CD8+ T cells, respectively when measured on day 3. However, the anti--apoptotic effect of a combined treatment of ATRA with doses 1, 5, 10 and 15 μM and IL--12 was recovered by day 5 (**[Fig. 9b](#F9){ref-type="fig"}**).

![Impacts of treatment with ATRA alone or in combinational with IL--12 on the antigen--specific activation of CD8+ T cells. OT--1 (CD8+) T cells were harvested from spleen and LN of naïve TCR transgenic mice and 1 × 106 cells were cultured in RPMI medium and stimulated with the MHC class--I peptide SIINFEKL from OVA albumin in the presence or absence of different concentration of ATRA (A). A separate set of ATRA--treated cells were concomitantly treated with 10 ng/ml IL--12 (B). Cells were harvested on day 5 post treatment and their apoptosis was determined by annexin--v binding assay.](JMedLife-04-399-g009){#F9}

Discussion {#sec1-4}
==========

CD8+ T cells are a critical component of the cellular immune response. They play an important role in the control of viral infection and eliminating cells with malignant potential \[**[@R32]--[@R33]**\]. However, attempts to generate and expand human CD8+ T cells *in vitro* for an adoptive immunotherapy had been conducted with limitation of the very low frequency of CD8+ T cells in blood. Therefore, several expansion protocols were developed to obtain large and efficient numbers of human CD8+ T cells for use in adoptive immunotherapies \[**[@R34]**\]. In this study IL--12 alone, but not IL--2 nor IL--15, as well as IGF--1 alone augmented the activation of CD8+ OT1 T cells. Interestingly, combination of IL --12 with IGF--1 sustained the expression of CD62L on OT1 cells. Analysis of the activation--induced cell death (apoptosis) of OT1 cells showed that addition of only IL--12 or IGF--1 alone, but not IL--2, IL--15 or T--α1, to Ag--stimulated CD8+ T cells decreased the percentage of apoptosis of these cells.

*In vitro* or *in vivo* treatment with IL--12 resulted in enhanced activity of T and NK cells which is characterized by increased secretion of IFN--γ \[**[@R31]**\]. Such enhanced immune response is, in part, the result of the direct stimulation of antigen presenting cells. A previous study by Salem *et al.* \[**[@R35]**\] showed that paracrine administration of IL--12 enhanced the functional capability of spleen dendritic cells to present peptide to naïve CD8+ T cells. IL--12 can also directly affect the development of CD8+ T cell--mediated responses \[**[@R32]**\]. By signaling directly through its receptor on CD8 T cells, IL--12 influences their differentiation to favor the generation of fully activated effectors \[**[@R34]**\]. It is known that optimal clonal expansion and acquisition of effector function requires a third signal that can be provided by IL--12 and that, in the absence of third signal, tolerance can occur \[**[@R9]--[@R10]**\]. In support of these findings, Chang *et al.* \[**[@R36]**\] reported that IL--12 priming at the time of antigenic stimulation increased the primary expansion of CD8+ T cells by reducing cell death, rather that by increasing cell proliferation, resulting in a larger CD8+ T cell memory pool. The ability of IL--12 to enhance proliferation of activated CD8+ T cells has been associated with enhanced expression of IL--2Rα in response to IL--12R engagement \[**[@R10]**\]. IL--12R expression is upregulated upon T cell receptor (TCR) activation \[**[@R37]**\], however low levels of expression were reported in resting NK cells, dendritic cells and B cell lines \[**[@R38]--[@R39]**\]. Historically, the expression of IL--12R was confined to activated Th1 cells \[**[@R40]--[@R41]**\], however the pivotal role of IL--12 in providing third signal for the clonal expansion of naïve CD8+ T cells, demonstrates a similar pattern of expression on activated CD8+ T cells \[**[@R10]**\].

IGF--1 has been implicated to play a regulatory role in T cell development and in T cell function \[**[@R42]**\]. *In vivo* activated T lymphocytes exhibit altered expression of IGF-- 1 receptor compared to the naïve T lymphocyte pool \[**[@R43]**\]. IGF--1 receptors were readily detectable on a wide variety of the immune cells, including T cells, B cells and monocytes, but the binding capacity for IGF--1 was monocytes, B cells and T cells. The level of IGF--1 receptor expression was increased several--fold after stimulation of both CD4+ and CD8+ T--cell subsets. IGF--1 is also expressed in many tumor cell lines and had a role in both normal cell proliferation and in the growth of cancers. Several approaches to target IGF--1 signaling resulted in the inhibition of the growth of a broad range of tumor cells \[**[@R44]**\]. IGF--1 was shown to protect cells from apoptosis by different stimuli and conditions \[**[@R45]**\]. It may alter homeostasis in the immune system by modulating lymphocyte generation and survival \[**[@R13]**\].

Mice deficient in dendritic epidermal T cells had a notable increase in epidermal apoptosis that was abrogated by the addition of IGF--1 \[**[@R46]**\]. T cell death--associated gene 51 plays an important role in the anti--apoptotic effects of IGF--I. Thus, effective strategies to generate competent CD8+ T cells for adoptive transfer should promote not only the generation of key subpopulations with superior anti--tumor activity, but also the maintenance of their viability *in vivo*. The present results suggest that antigen priming in the presence of both IL-- 12 and IGF--1 accomplishes both ends. It not only directly modulates the expression of CD62L on activated CD8+ T cells, but also selectively promotes the survival of activated CD8+ T cells expressing high levels of CD62L. In conclusion, the present results indicate that the activation phenotype and the survival of antigen--specific T cells can be differentially modulated by different immunomodulatory factors, where, interleukin-- 12 and IGF--1 induced the favorable effect. These results have a significant implication for T cell adoptive immunotherapy in different settings.
